DHEA Shown to Reduce Menopausal Symptoms
DHEA, a hormone secreted by the adrenal glands, has been shown to reduce menopausal symptoms and may be used as an alternative to hormone replacement therapy. A study published in Climacteric recruited 48 postmenopausal women to take vitamin D and calcium, DHEA (10 mg/day), HRT, or tibolone (a synthetic steroid). The one-year study found that menopausal symptoms and sexual function improved among women taking DHEA or HRT, while those taking vitamin D and calcium did not have a significant improvement in symptoms.
Researchers explain that while a larger study could confirm these initial findings, this study shows DHEA could be a potential alternative for women that have problems taking conventional HRT.
As we age, DHEA levels naturally decrease leaving the body susceptible to age-related illnesses.
DHEA can also:
Increase Energy
Balance Mood
Strengthen Immunity
Support Bone Density
Sustain Cognitive Function
The recommended dosage for DHEA is 25 mg to 100 mg/day for men and 5 mg to 25 mg/day for women.
NUTRASCRIPTIVES RECOMMENDED SUPPLEMENTS
References
Genazzani AR, Stomati M, Valentino V, Pluchino N, et al. Effect of 1-year, low-dose DHEA therapy on climacteric symptoms and female sexuality. Climacteric. 2011 Dec; 14(6):661-668.
Kedziora-Kornatowska K, Beszcynska-Oles R, Kornatowski T, Szadujkis-Szadurski L. The analysis of dehydroepiandrosterone sulphate concentration in elderly age women depending on coexisting disease states. Adv Med Sci. 2007; 52(1): 126-130.
Maes M, Mihaylova I, De Ruyter M. Decreased dehydroepiandrosterone sulfate but normal insulin-like growth factor in chronic fatigue syndrome (CFS): relevance for the inflammatory response in CFS. Neuro Endocrinol Lett. 2005 Oct; 26(5):487-492.
Tellez N, Comabella M, Julia E, et al. Fatigue in progressive multiple sclerosis is associated with low levels of dehydroepiandrosterone. Mult Scler. 2006 Aug; 12(4):487-494.
Von Muhlen, D, Laughlin, GA, et al. Effect of dehydroepiandrosterone supplementation on bone mineral density, bone markers, and body composition in older adults: the DAWN trial. Osteoporos Int. 2008 May; 19(5):699-707.
Wolkowitz OM, Reus VI, Keebler A, et al. Double-blind treatment of major depression with dehydroepiandrosterone. Am J Psychiatry. 1999 Apr; 156(4):646-649.
